Symbolbild · KI-generiert
Xeris Biopharma Holdings, Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Xeris Biopharma is an Irish specialty pharmaceutical company focused on the development and commercialisation of ready-to-use injectable products based on its XeriSol and XeriJect technologies. The company markets, amongst other products, a glucagon auto-injector pen for the emergency treatment of severe hypoglycaemia. Xeris has commercial operations in the United States and the United Kingdom.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. | XERS | NASDAQ | 1,39 Mrd. USD |
| Monte Rosa Therapeutics, Inc. | GLUE | NASDAQ | 1,40 Mrd. USD |
| Perrigo Company plc | PRGO | NYSE | 1,40 Mrd. USD |
| ArriVent BioPharma, Inc. | AVBP | NASDAQ | 1,39 Mrd. USD |
| CONMED Corporation | CNMD | NYSE | 1,39 Mrd. USD |
| Anbio Biotechnology | NNNN | NASDAQ | 1,42 Mrd. USD |
| MoonLake Immunotherapeutics | MLTX | NASDAQ | 1,36 Mrd. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.